Candidate Compounds Covid19

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

• reviews on covid drug development
• scouting ideas

• Patients on biologicals
• HMGB1, RAGE
• pre-Interleukin 6
• post-Interleukin 6
• pre-TNFalpha
• post-TNFalpha
• pre-Interleukin 17
• post-Interleukin 17
• pre-Interleukin 1
• post-Interleukin 1
• Inflammasome colchicine
• Methotrexate
• other anti-inflammatory
• NK-kappaB
• STAT 3
• JAK Janus Kinase
• Corticosteroids
• Cytokine absorbers
• Target Complement system
• Target Extracellular traps
• Target Neurophils
• Target Mast cells and kinins
• TGF beta
• Immunosuppressants
• Anticoagulant in covid19
• Antioxidants
• HIF-EPO-Iron
• Stem cells
• MDSC cells
• Interferons
• cAMP cGMP PDE NO
• TRPV* channels
• Retinoids
• Protease inhibitors
• Tyrosine kinase inhibitors
• Antineoplastic agents, traditional
• Mouthrinses
• Adenosinergic signaling
• Purinergic signaling
• Nicotinergic signaling

• other single compounds
• Retargeted single compounds
• Hydroxychloroquine
• Target ACE2, Spike protein
• Target TMPRSS2, Spike protein any other covid targed herein
• other antiviral compounds
• AV Remdesivir
• AV Lopinavir
• AV Ivermectin
• AV Arabidol
• AV Favipiravir

• Antibiotics

• Vitamin D
• Anorganic nutrients Magnesium
• Anorganic nutrients Selenium
• Anorganic nutrients Zinc
• Anorganic nutrients Lithium
• Anorganic nutrients Copper
• Anorganic nutrients Bismuth
• Nutrition, general
• Exercise, Vibration

• Traditional Chinese Medicine
• Natural compounds

• Statins
• Antidiabetic compounds, any
• RSP - On RAS drugs
• RSP - On NSAIDs

• Reconvalescent blood products, Passive vaccine
• Plasmapheresis

• Immunodeviation e.g. by adjuvants or other vaccinations
• Radiation therapy
• Phototherapy
• Active vaccine

• Treatment other concepts

32445955 2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"

32426002 2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.

32376108 2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.

32426090 2020. COVID-19, asthma, and biologic therapies: What we need to know.

32514854 2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.

32558354 2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.

32562159 2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.

32592145 2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.

32562594 2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.

32578073 2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.
32577840 2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.

32588335 2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.

32552021 2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.

32551560 2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.

32561608 2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.
32574109 2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.

32567239 2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.

32587103 2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?

32565309 2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.

32557955 2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.

32579012 2020. COVID-19. Immunothrombosis and the gastrointestinal tract.

32593196 2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.

32583729 2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.

32568012 2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.

32547694 2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.

32566569 2020. Appealing for efficient, well organized clinical trials on COVID-19.

32593613 2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.

32532425 2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?
32557557 2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?

32383125 2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.

32385712 2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?

32610153 2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.

32584416 2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.

32536693 2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?

32572383 2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.

32548601 2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.
32548600 2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.

32544611 2020. Development of child immunity in the context of COVID-19 pandemic.

32417594 2020. Supplements for COVID-19: A modifiable environmental risk.

32407539 2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?

32311763 2020. Off-Label Therapies for COVID-19-Are We All In This Together?

32388748 2020. Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?

32575032 2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.

32392494 2020. Sample sizes in COVID-19-related research.

32513242 2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.
32513225 2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?
32487260 2020. Precision medicine for COVID-19: a call for better clinical trials.

32550078 2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.

32563554 2020. Should we unstress SARS-CoV-2 infected cells?

32605149 2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.

32520770 2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.

32574379 2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.

32541129 2020. Intermittent high dosage oxygen treats COVID-19 infection: the Chinese studies.
32541128 2020. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure.

32544799 2020. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.

32399192 2020. Recent advances in influenza vaccines.

32540428 2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.
32537482 2020. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach.

32552595 2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.

32552462 2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.

32543978 2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.

32605306 2020. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.

32553502 2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.

32551855 2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.

32454982 2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.

32582350 2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.
32600410 2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.

32539990 2020. A minimal common outcome measure set for COVID-19 clinical research.

32537610 2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.

32540604 2020. Iodine, a preventive and curative agent in the COVID-19 pandemic?

32554324 2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.

32563970 2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.

32545268 2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.

32540682 2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.

32548259 2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.
32601278 2020. Numerical evaluation of spray position for improved nasal drug delivery.

32576928 2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.

32583289 2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.
32557317 2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.

32563584 2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.

32595360 2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.
32595359 2020. Potentials of plant-based substance to inhabit and probable cure for the COVID-19.

32565126 2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.